COMPARE · Data as of August 21, 2026
ALNY vs PTCT
Verdict: Side-by-side breakdown using the Bull Rankings model. ALNY scored 75.0, PTCT scored 24.7 — ALNY leads.
Compare another set
ALNY
Alnylam Pharmaceuticals, Inc.
75
$236.22 · $31.6B
fundamentals as of
Score gap
50.3
ALNY leads
PTCT
PTC Therapeutics, Inc.
24.7
$69.82 · $5.8B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthALNY+65.2%
- Highest qualityALNY67 / 100
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
ALNY
stronger →← stronger
PTCT
67
Qualityreturns · margins · balance sheet
39
99
Growthrevenue & earnings expansion
15
64
Valuevaluation vs sector peers
26
ALNY is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
ALNY
PTCT
$465mC
FCF
-$40mF
+65.2%A
Rev
-42.8%F
2.21D
D/E
—
41.2xC
P/E
—
0.46A
PEG
—
—
P/S
5.8xB
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
ALNY
PTCT
189% above
Price vs fair valuelower is cheaper
—
~43%/yr
Growth the price implies10-yr FCF · lower = less priced in
—
-74%
1-yr DCF upside
—
-65%
5-yr DCF upside
—
-48%
10-yr DCF upside
—
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ALNY
Why this score
- Diluting shareholders
PTCT
Why this score
- Diluting shareholders
The companies
ALNYAlnylam Pharmaceuticals, Inc.
Why now
Biotechnology · market cap $31.6b. Down 52% from 52-week high of $495.55 — deep drawdown territory. Revenue growing +65% — in hypergrowth territory. PEG 0.46 — paying under fair value for the growth rate. 26 sell-side analysts rate this a Buy with a mean 1-yr target of $370.20 (implying +57% upside).
Moat
Net margin 20% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 54% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
D/E 2.21 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Down 52% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 41x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
PTCTPTC Therapeutics, Inc.
Why now
Biotechnology · market cap $5.8b. Down 23% from 52-week high of $90.87 — deep drawdown territory. Revenue -43% — in contraction; any catalyst that reverses this triggers re-rating. 14 sell-side analysts rate this a Buy with a mean 1-yr target of $99.29 (implying +42% upside).
Moat
ROE 23% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$40m) — capital raises or debt issuance likely required; dilution / leverage risk. Revenue contracting -43% — the operational turn is not yet visible in the top line. Currently unprofitable (margin -3.8%) — path to GAAP profitability is the core thesis risk.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ALNY and PTCT diverge
On the headline score the gap is 50.3 points in favor of ALNY. The widest single difference is Growth, where ALNY leads by 83.8 points.
- GrowthALNY 98.5 · PTCT 14.7ALNY +83.8
- ValueALNY 64.1 · PTCT 26.0ALNY +38.1
- QualityALNY 66.8 · PTCT 39.2ALNY +27.6
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.